A team of Skadden, Arps, Slate, Meagher & Flom litigators last week beat back a putative federal securities class action in North Carolina against biopharmaceutical company Cempra, Inc.

The company and its top executives were sued for making allegedly false and misleading statements about the safety of the company’s lead product, solithromycin. The drug is being developed for the treatment of community-acquired bacterial pneumonia (the leading cause of death due to infection in the United States).

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]